Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Glaxo finds execs selling resveratrol supplements

This article was originally published in The Tan Sheet

Executive Summary

A pair of GlaxoSmithKline executives involved with the pharma giant's development of resveratrol-based drugs were disciplined after GSK found them moonlighting on the board of a nonprofit selling resveratrol supplements, according to Aug. 13 media reports. Christoph Westphal and Michelle Dipp joined Glaxo when it acquired Sirtris Pharmaceuticals, where they were principal executives, in 2008. Though Westphal and Dipp say they had informed the parent company of their involvement with the Healthy Lifespan Institute, apparently GSK was unaware the nonprofit sold resveratrol supplements at $540 for a year supply. GSK has asked Westphal and Dipp to leave the Healthy Lifespan Institute's board. Though resveratrol currently is found mainly in supplements touting anti-aging benefits, Glaxo acquired Sirtris for $720 million in hopes that its red wine extract technology will eventually bear fruit and yield multi-billion-dollar pharmaceuticals (1"The Tan Sheet" April 28, 2008, In Brief)

You may also be interested in...



Glaxo Shifts Rx Resveratrol Focus But Nutritional Interest Still Strong

GlaxoSmithKline's decision to abandon its pharmaceutical research program on resveratrol leaves the red wine extract exclusively to the nutritionals industry.

GSK buys Sirtris

GlaxoSmithKline will acquire Sirtris Pharmaceuticals for approximately $720 million through a cash tender offer of $22.50 per share, which is an 84 percent premium on Sirtris' closing price April 22 - the day the deal was announced. GSK says the acquisition will "significantly enhance its metabolic, neurology, immunology and inflammation research efforts by establishing a presence in the field of sirtuins," a seven-member family of proteins long thought to play a role in the aging process, with "potentially transformative" benefits addressing diseases such as diabetes, muscle wasting and neuron-degeneration. Sirtris' lead compound, the resveratrol formulation SRT501, "significantly" lowered glucose in an oral glucose tolerance test conducted as part of a 28-day Phase 1b clinical study in type 2 diabetes patients, the firm said in January (1"The Tan Sheet" Jan. 14. 2008, In Brief). Sirtris will become part of GSK's Drug Discovery division while operating in Cambridge, Mass., as an autonomous unit. The deal is subject to closing conditions, but the firms expect the tender offer to commence in May and close in the second quarter of 2008...

J&J To Power Ahead With 10 Launches In Four Years

 Johnson & Johnson has achieved exceptional growth in recent years, and a raft of new products is set to sustain it further. 

Topics

UsernamePublicRestriction

Register

PS104406

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel